Document is current
Any future updates will be listed below
-
Authors
Hernández-Santacana, Marc
Balado-Simó, Pablo
Mansilla-Polo, Miguel
Riera-Monroig, Josep https://orcid.org/0000-0001-9265-1019
- License Information
-
More Information
Article History
Received: 27 April 2026
Accepted: 23 June 2026
First Online: 7 July 2026
Declarations
Conflict of interest: Marc Hernández-Santacana and Pablo Balado-Simó have received support for attending meetings from Abbvie, Almirall SA, Johnson & Johnson, Leo Pharma, Lilly and Sanofi, Miguel Mansilla-Polo has acted as a speaker for Novartis, UCB and Almirall and has received support for attending meetings from AbbVie, Johnson & Johnson, Leo Pharma, Lilly and Sanofi, Josep Riera-Monroig has acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis: AbbVie, Almirall SA, Amgen, Bristol Myers Squibb, Johnson & Johnson, Leo-Pharma, Lilly, Novartis and UCB. Josep Riera-Monroig is an Editorial Board member for Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
